Skip to Navigation
Skip to Main Content
Skip to Related Content
to view your mail
Yahoo Finance Plus
U.S. Markets closed
Russell 2000 Futures
Bonus BioGroup Ltd. (BONS.TA)
Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
Add to watchlist
At close: 05:24PM IST
33 reactions on $BONS.TA conversation
Sign in to post a message.
Bonus Bio submitted request to the ministry of health in Israel for approval for emergency use of MesenCure to treat severe corona patients.
SIBF purchased 35 M shares.
I was hoping it would bounce the stock up.
why big volume today???whatsup
In phase 3 with a possible EUA soon. this could be a millionaire maker.
Anyone have any insights on where this stock is heading in the near term?
The latest results released right before Thanksgiving, showing 70% lower mortality for severe Covid, are simply astounding. I'm a physician, and I treat these patients in the hospital, and the current treatments are mediocre at best. This is a game-changer. We desperately need treatments for people with severe Covid - we now have monoclonal antibodies for non-severe Covid, but when patients are hospitalized, all we have is remdesivir (mediocre at best, even the WHO says we should not bother using it) and steroids. And Actemra, which is in a nationwide shortage, and not great. Mesenchymal stem cell therapy to decrease inflammation changes everything, and new variants won't matter, since this therapy is not based on antibodies that may not be effective on new variants, but based on fighting the inflammation that is what actually kills these patients. I've signed a lot of death certificates due to Covid, and I can tell you that a treatment like this can change treatment dramatically.
Good phase II results and the stock crashes?
What’s the difference in shares?
This data indicates that MesenCure is at least 4 (!) times more effective than the best currently available standard of care for severe Covid-19 patients.
The question is: why is this stock so cheap?
This company stock is sold on Tel Aviv exchange
corona cure, test succeed in animals. next step humane trial. this small company may gain huge!!
News article in the Jerusalem Post re companies successful treatment of severe pulmonary issues !!
ride this to 5.00 or 7.00 more than a covid therapy here...
Bonus BioGroup Reports Resounding Success in Phase-I Clinical Trials for Regenerative COVID-19 Treatment
TEL AVIV, ISRAEL / ACCESSWIRE / July 19, 2021 / Bonus BioGroup LTD (TASE:BONS), an Israeli clinical-stage biotechnology company, announced further improvements in key parameters measured in phase I/II Clinical Trials for its advanced cell therapy product, MesenCure. The latest report follows Bonus BioGroup's May 27th announcement of MesenCure'scomplete success in the treatment of severe COVID-19 patients suffering from life-threatening pneumonia and acute respiratory distress. These new findings emerge against the backdrop of the rapid spread of new SARS-CoV-2 variants, a decrease in vaccine effectiveness, and a rise in infection rates worldwide.
The latest round of results revealed an improvement in parameters associated with patient prognosis, recovery, and chance of survival. More specifically, Bonus BioGroup noted a reduced risk of multiorgan dysfunction, heart/kidney injuries, and venous thromboembolism (VTE) in COVID patients after the first dose of MesenCure, with a cumulative effect observed when multiple doses were administered.
These findings were obtained after the Company completed an additional analysis of the results it obtained in a Phase I/II clinical trial held at the Rambam Health Care Campus in Haifa, Israel that was geared towards evaluating the safety and efficacy of MesenCure in the treatment of severe COVID-19 patients. In such cases, inflammation and tissue damage are detected not only in the lungs, but also in the heart and the kidneys at levels more than ten times higher than those observed in milder patients.
1. Bonus BioGroup
Bonus Biogroup (TASE:BONS) is an Israel-based innovator that is working to apply cell therapy and regenerative medicine to the treatment of severe COVID-19 cases. On July 19, Bonus reported further improvements in key parameters tested in Phase I/II clinical trials for its MesenCure treatment.
Bonus’ newfangled MesenCure relies on activated mesenchymal stromal (stem) cells taken from healthy adult donors. Using these stem cells, MesenCure works to reduce severe COVID-related symptoms such as acute pneumonia and organ failure that are caused by a massive inflammatory reaction (viz. Cytokine storm) in patients suffering from severe COVID.
Given MesenCure’s measured 100% success rate to-date, the Israeli Ministry of Health has approved the continuation of Phase II clinical trials, set to take place at Haifa’s Rambam Medical Center.
Big volume today, early human covid treatment trials extremely successful.... this could be big.
One of the most intresting companies....
This should be headlines around the world
Effective treatment for COVID
The monthly child tax credit payments are done—here’s what will replace it
Stocks close lower in choppy trading session
Yahoo Finance Video
Kraft's Oscar Mayer taps into nostalgia, self-care with Bologna beauty mask
Advertise with us
© 2022 Yahoo. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research